Print  |  Font Size Change Font Size

The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv®4, Bunavail™5, Probuphine®6) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

What is ZubsolvĀ®?

Zubsolv® is a schedule III buprenorphine/naloxone combination medication specifically indicated (and FDA approved) for the treatment of opioid addiction. Along with Suboxone®, its generic equivalents, Subutex® (discontinued in the US), its generic equivalents, Zubsolv is a medication subject to DATA-2000.

FDA approved on July 3, 2013 and commercially launched in September 2013, Zubsolv is the first brand name competitor to Suboxone. Manufacturer copay card available - up to $225 off

Zubsolv has a higher bioavailability than Suboxone and as a result comes in different doses than Subxone or generics. Zubsolv comes in sublingual tablet sizes of 5.7-mg/1.4-mg (buprenorphine/naloxone), and 1.4-mg/0.36-mg (buprenorphine/naloxone) both have equal bioavailability to 8mg/2mg and 4mg/1mg of competing buprenorphine/naloxone products, respectively. Sub-to-Zub dose conversion tool

UPDATE: On March 6, 2015 Orexo US, Inc. announced the FDA approval of the new 8.6mg/2.1mg dosage strength of ZUBSOLV®. This corresponds to 12mg/3mg of generic bup/nx dosing.

Zubsolv is individually packaged to reduce accidental pediatric exposure. 

See the Zubsolv website for more info:

Back to FAQs

The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
  6. Probuphine FDA approved 5/26/2016 - FDA Probuphine press release